Just two weeks after Biogen completed its buyout of Reata Pharmaceuticals, the combined company is trimming its staff.
6 months ago

A new Plano office tower built by Trammell Crow Co. for Reata Pharmaceuticals Inc. is back on the sublease market.
5 months ago

STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS ... Biogen confirms that today Reata Pharmaceuticals announced in a...
7 months ago

Biogen to acquire Reata Pharmaceuticals in $7 billion deal ... Biogen on Friday said it would acquire Reata Pharmaceuticals, the maker of an...
9 months ago

Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO...
9 months ago

Reata Pharmaceuticals Inc.'s RETA stock soared 51.5% after Biogen Inc. BIIB said it would buy the drug maker for $7.3 billion in cash.
9 months ago

Vinson & Elkins advised Reata Pharmaceuticals Inc. (“Reata”), a global biopharmaceutical company committed to developing and commercializing...
9 months ago

Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved...
7 months ago

Biogen has entered into a definitive agreement to acquire Reata Pharmaceuticals for an enterprise value of $7.3bn.
9 months ago

Following Biogen's $7.3 billion acquisition of Reata Pharmaceuticals in July 2023, the drug on Monday was approved in the European Union for...
2 months ago